Short answer
ENANTA PHARMACEUTICALS INC (ENTA) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $14M (down 21.6% year over year) with net income of −$20M.
Q2 2026 key financials · XBRL
- Revenue
- $14M
- −21.6% YoY · −16.3% QoQ
- Net income
- −$20M
- −6.8% YoY · −49.0% QoQ
- Operating margin
- -120.0%
- EPS (diluted)
- −$0.67
- +21.2% YoY · −48.9% QoQ
Source: XBRL data from the ENANTA PHARMACEUTICALS INC (ENTA) Q2 2026 10-Q on SEC EDGAR. USD.
ENANTA PHARMACEUTICALS INC Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to risk factors identified in provided text
- Liquidity risk: $211,493 cash, cash equivalents, and marketable securities expected to fund operations for at least 12 months
- Financial risk: Royalty-sale liability $125,073 with 12.8% effective annual imputed interest rate
- Market risk: MAVYRET/MAVIRET royalties depend on AbbVie sales and face competition from other HCV treatments
- Regulatory risk: Product candidates require extensive clinical testing and regulatory approvals before commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ENANTA PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.